March 12, 2019 06:06 PM EDT
Deals

Bris­tol-My­ers CEO Caforio wants M&A dis­si­dents to know there's been no 'high lev­el' over­tures about buy­ing the com­pa­ny since '17

John Carroll

Editor & Founder

Bris­tol-My­ers Squibb CEO Gio­van­ni Caforio took to the cen­ter stage at the Cowen Health Care Con­fer­ence to­day and tried his very best to kick out at least one of the legs hold­ing up the per­sis­tent case be­ing made against the big Cel­gene buy­out.

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

A service from the Financial Times